All Stories

  1. Characterizing PRN Use of Psychotropic Medications for Acute Agitation in Canadian Long-Term Care Residents with Dementia Before and During COVID-19

    Article • Journal of Alzheimer s Disease Reports, June 2023, IOS Press

    Krista L Lanctot

  2. Lipid Peroxidation as a Marker of Apathy and Executive Dysfunction in Patients at Risk for Vascular Cognitive Impairment

    Article • Journal of Alzheimer s Disease, September 2022, IOS Press

    Krista L Lanctot

  3. Glutathione Peroxidase Activity Is Altered in Vascular Cognitive Impairment-No Dementia and Is a Potential Marker for Verbal Memory Performance

    Article • Journal of Alzheimer s Disease, February 2021, IOS Press

    Krista L Lanctot

  4. Endostatin as a Mediator Between Endothelial Function and Cognitive Performance in Those at Risk for Vascular Cognitive Impairment

    Article • Journal of Alzheimer s Disease, June 2020, IOS Press

    Krista L Lanctot

  5. Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation

    Article • Journal of Geriatric Psychiatry and Neurology, September 2019, SAGE Publications

    Krista L Lanctot

  6. 24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer’s Disease: Analyses from a Clinical Trial with Nabilone

    Article • Journal of Alzheimer s Disease, September 2019, IOS Press

    Krista L Lanctot

  7. The value of screening for cognition, depression, and frailty in patients referred for TAVI

    Article • Clinical Interventions in Aging, May 2019, Dove Medical Press

    Krista L Lanctot

  8. Psychometric Properties of Apathy Scales in Dementia: A Systematic Review

    Article • Journal of Alzheimer s Disease, November 2018, IOS Press

    Krista L Lanctot

  9. Ceramide Accumulation Is Associated with Declining Verbal Memory in Coronary Artery Disease Patients: An Observational Study

    Article • Journal of Alzheimer s Disease, July 2018, IOS Press

    Krista L Lanctot

  10. Detection of Apathy in Alzheimer Patients by Analysing Visual Scanning Behaviour with RNNs

    Article • July 2018, ACM (Association for Computing Machinery)

    Krista L Lanctot

  11. A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise

    Article • Journal of Alzheimer s Disease, October 2017, IOS Press

    Krista L Lanctot

  12. Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation

    Article • Expert Opinion on Drug Safety, July 2017, Taylor & Francis

    Krista L Lanctot

  13. Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment

    Article • Journal of Alzheimer s Disease, June 2017, IOS Press

    Krista L Lanctot

  14. Prevalence, neurobiology, and treatments for apathy in prodromal dementia

    Article • International Psychogeriatrics, April 2017, Cambridge University Press

    Krista L Lanctot

  15. Baseline Oxidative Stress Is Associated with Memory Changes in Omega-3 Fatty Acid Treated Coronary Artery Disease Patients

    Article • Cardiovascular Psychiatry and Neurology, January 2017, Hindawi Publishing Corporation

    Dr Gustavo Scola, Krista L Lanctot

  16. Visual Selective Attention Toward Novel Stimuli Predicts Cognitive Decline in Alzheimer’s Disease Patients

    Article • Journal of Alzheimer s Disease, December 2016, IOS Press

    Krista L Lanctot

  17. Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease

    Article • November 2016, Dove Medical Press

    Krista L Lanctot

  18. Pharmacological Management of Agitation and Aggression in Alzheimer’s Disease: A Review of Current and Novel Treatments

    Article • Current Alzheimer Research, August 2016, Bentham Science Publishers

    Krista L Lanctot

  19. Apathy and Attentional Biases in Alzheimer’s Disease

    Article • Journal of Alzheimer s Disease, March 2016, IOS Press

    Krista L Lanctot

  20. Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study

    Article • September 2015, Dove Medical Press

    Krista L Lanctot

  21. A meta-analysis of lipid peroxidation markers in major depression

    Article • September 2015, Dove Medical Press

    Krista L Lanctot

  22. Latrepirdine for Alzheimer's disease

    Article • Cochrane Database of Systematic Reviews, April 2015, Wiley

    Krista L Lanctot

  23. Reply to: Serum Zinc and the Risk of Depression in Men: Observations from a 20-Year Follow-up Study

    Article • Biological Psychiatry, February 2015, Elsevier

    Krista L Lanctot

  24. Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition

    Article • International Psychogeriatrics, October 2014, Cambridge University Press

    Krista L Lanctot

  25. Depressive Symptoms Predict Non-Adherence to Exercise-Based Rehabilitation in Participants with Type 2 Diabetes Mellitus

    Article • Canadian Journal of Diabetes, October 2014, Elsevier

    Krista L Lanctot

  26. Kynurenine and depressive symptoms in a poststroke population

    Article • September 2014, Taylor & Francis

    Paul Kudlow, Krista L Lanctot

  27. Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study

    Article • Journal of Neuroinflammation, July 2014, Springer Science + Business Media

    Krista L Lanctot

  28. P4‐180: DESIGN OF THE SARTAN‐AD TRIAL

    Article • Alzheimer s & Dementia, July 2014, Wiley

    Krista L Lanctot

  29. P3‐006: MINING THE NEURAL AND PLASMA PHOSPHOLIPIDOME TO IDENTIFY CRITICAL LIPID DETERMINANTS OF ALZHEIMER'S DISEASE CONVERSION

    Article • Alzheimer s & Dementia, July 2014, Wiley

    Krista L Lanctot

  30. Cardiopulmonary Fitness Correlates with Regional Cerebral Grey Matter Perfusion and Density in Men with Coronary Artery Disease

    Article • PLoS ONE, March 2014, PLOS

    Krista L Lanctot

  31. Challenges in the pharmacotherapy of apathy in Alzheimer's disease

    Article • Neurobiology of Aging, March 2014, Elsevier

    Krista L Lanctot

  32. The Platelet Activating Factor PC(O-18:3/2:0) is Associated with Apathy Independently of Depressive Symptoms in Depressed Patients with Coronary Artery Disease

    Article • American Journal of Geriatric Psychiatry, March 2014, Elsevier

    Krista L Lanctot

  33. Assessing Cognitive Effects of Anticholinergic Medications in Patients With Coronary Artery Disease

    Article • Psychosomatics, January 2014, Elsevier

    Krista L Lanctot

  34. Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease

    Article • Canadian Geriatrics Journal, December 2013, Canadian Geriatrics Society

    Krista L Lanctot

  35. Zinc in Depression: A Meta-Analysis

    Article • Biological Psychiatry, December 2013, Elsevier

    Krista L Lanctot

  36. Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study

    Article • BMC Geriatrics, December 2013, Springer Science + Business Media

    Krista L Lanctot

  37. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial

    Article • International Psychogeriatrics, October 2013, Cambridge University Press

    Krista L Lanctot

  38. Platelet activating factors in depression and coronary artery disease: A potential biomarker related to inflammatory mechanisms and neurodegeneration

    Article • Neuroscience & Biobehavioral Reviews, September 2013, Elsevier

    Krista L Lanctot

  39. O3–04–02: Using visual attention to detect apathy in Alzheimer's disease

    Article • Alzheimer s & Dementia, July 2013, Wiley

    Krista L Lanctot

  40. Potential roles of zinc in the pathophysiology and treatment of major depressive disorder

    Article • Neuroscience & Biobehavioral Reviews, June 2013, Elsevier

    Krista L Lanctot

  41. Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future

    Article • Alzheimer s & Dementia, April 2013, Wiley

    Krista L Lanctot, Dr Chiadi U Onyike

  42. Safety and Efficacy of Methylphenidate for Apathy in Alzheimer’s Disease

    Article • The Journal of Clinical Psychiatry, April 2013, Physicians Postgraduate Press, Inc

    Krista L Lanctot

  43. Interleukin-17 in post-stroke neurodegeneration

    Article • Neuroscience & Biobehavioral Reviews, March 2013, Elsevier

    Krista L Lanctot

  44. Higher Cortisol Predicts Less Improvement in Verbal Memory Performance after Cardiac Rehabilitation in Patients with Coronary Artery Disease

    Article • Cardiovascular Psychiatry and Neurology, January 2013, Hindawi Publishing Corporation

    Krista L Lanctot

  45. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

    Article • Alzheimer s Research & Therapy, January 2013, Springer Science + Business Media

    Krista L Lanctot

  46. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012

    Article • Alzheimer s Research & Therapy, January 2013, Springer Science + Business Media

    Krista L Lanctot

  47. Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia

    Article • Alzheimer s & Dementia, October 2012, Wiley

    Krista L Lanctot

  48. P2‐358: Safety profile of methylphenidate in apathetic patients with Alzheimer's disease: Apathy in Dementia Methylphenidate Trial (ADMET)

    Article • Alzheimer s & Dementia, July 2012, Wiley

    Krista L Lanctot

  49. P3‐377: Apathy in dementia methylphenidate trial (ADMET): Recruiting for apathy in Alzheimer's disease

    Article • Alzheimer s & Dementia, July 2012, Wiley

    Krista L Lanctot

  50. P1‐003: Apathy in Dementia Methylphenidate Trial (ADMET): Preliminary efficacy report

    Article • Alzheimer s & Dementia, July 2012, Wiley

    Krista L Lanctot

  51. O4‐12‐03: Methylphendiate in treatment for apathy in Alzheimer's disease

    Article • Alzheimer s & Dementia, July 2012, Wiley

    Krista L Lanctot

  52. Effects of omega-3 fatty acids on cognitive performance: a meta-analysis

    Article • Neurobiology of Aging, July 2012, Elsevier

    Krista L Lanctot

  53. P2‐040: Plasma ceramide concentrations are associated with change in verbal memory performance in patients undertaking cardiac rehabilitation

    Article • Alzheimer s & Dementia, July 2012, Wiley

    Krista L Lanctot

  54. The Current Status of Alzheimer's Disease Treatment

    Article • April 2012, Taylor & Francis

    Krista L Lanctot

  55. Exercise intervention and inflammatory markers in coronary artery disease: A meta-analysis

    Article • American Heart Journal, April 2012, Elsevier

    Krista L Lanctot

  56. Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimerʼs Disease Relieve Caregiver Burden?

    Article • Drugs & Aging, March 2012, Springer Science + Business Media

    Krista L Lanctot

  57. Dimebon for Alzheimer's disease

    Article • December 2011, Wiley

    Krista L Lanctot

  58. Current and Emerging Drug Treatment Options for Alzheimerʼs Disease

    Article • Drugs, October 2011, Springer Science + Business Media

    Krista L Lanctot

  59. The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease

    Article • CNS Neuroscience & Therapeutics, September 2011, Wiley

    Krista L Lanctot

  60. Verbal Memory Performance and Completion of Cardiac Rehabilitation in Patients With Coronary Artery Disease

    Article • Psychosomatic Medicine, September 2011, Wolters Kluwer Health

    Krista L Lanctot

  61. F1‐02‐05: Apathy in Alzheimer's disease: Towards an integrated research agenda

    Article • Alzheimer s & Dementia, July 2011, Wiley

    Krista L Lanctot

  62. Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimerʼs Disease

    Article • CNS Drugs, May 2011, Springer Science + Business Media

    Krista L Lanctot

  63. Memantine in dementia: a review of the current evidence

    Article • Expert Opinion on Pharmacotherapy, March 2011, Informa Healthcare

    Krista L Lanctot

  64. The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment

    Article • Journal of Neuroinflammation, February 2011, Springer Science + Business Media

    Krista L Lanctot

  65. Long-term use of cholinesterase inhibitors: till death do us part?

    Article • Neurodegenerative Disease Management, February 2011, Future Medicine

    Krista L Lanctot

  66. Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type

    Article • Ageing Research Reviews, February 2011, Elsevier

    Krista L Lanctot

  67. Major Depressive Disorder Predicts Completion, Adherence, and Outcomes in Cardiac Rehabilitation

    Article • The Journal of Clinical Psychiatry, November 2010, Physicians Postgraduate Press, Inc

    Krista L Lanctot

  68. A Meta-Analysis of Cytokines in Alzheimer's Disease

    Article • Biological Psychiatry, November 2010, Elsevier

    Krista L Lanctot

  69. The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease

    Article • CNS Drugs, November 2010, Springer Science + Business Media

    Krista L Lanctot

  70. Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts

    Article • International Psychogeriatrics, September 2010, Cambridge University Press

    Krista L Lanctot

  71. Cardiopulmonary Fitness Is Associated with Cognitive Performance in Patients with Coronary Artery Disease

    Article • Journal of the American Geriatrics Society, August 2010, Wiley

    Krista L Lanctot

  72. Relationship between hair cortisol concentrations and depressive symptoms in patients with coronary artery disease

    Article • Neuropsychiatric Disease and Treatment, June 2010, Taylor & Francis

    Krista L Lanctot

  73. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury

    Article • Brain Injury, June 2010, Taylor & Francis

    Krista L Lanctot

  74. A Meta-Analysis of Cytokines in Major Depression

    Article • Biological Psychiatry, March 2010, Elsevier

    Krista L Lanctot

  75. Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease

    Article • Psychoneuroendocrinology, November 2009, Elsevier

    Krista L Lanctot

  76. Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently‐obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease

    Article • International Journal of Geriatric Psychiatry, September 2009, Wiley

    Krista L Lanctot

  77. A brief history of poststroke depression neuroimaging

    Article • Aging Health, February 2009, Future Medicine

    Krista L Lanctot

  78. Commentary: Aβ(1–42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels

    Article • Experimental Neurology, August 2008, Elsevier

    Krista L Lanctot

  79. A functional neuroimaging study of appetite loss in Alzheimer’s disease

    Article • Journal of the Neurological Sciences, August 2008, Elsevier

    Krista L Lanctot, Dr Zahinoor Ismail

  80. Methylphenidate for the Treatment of Apathy in Alzheimer Disease

    Article • Journal of Clinical Psychopharmacology, June 2008, Wolters Kluwer Health

    Krista L Lanctot

  81. Management of behavioural and psychological symptoms of dementia and acquired brain injury

    Article • January 2008, Cambridge University Press

    Krista L Lanctot

  82. The serotonin transporter polymorphisms and major depression following traumatic brain injury

    Article • Brain Injury, January 2008, Taylor & Francis

    Krista L Lanctot

  83. Serotonin-1A receptors in frontotemporal dementia compared with controls

    Article • Psychiatry Research Neuroimaging, December 2007, Elsevier

    Krista L Lanctot

  84. Management of mild to moderate Alzheimer's disease and dementia

    Article • Alzheimer s & Dementia, September 2007, Wiley

    Krista L Lanctot

  85. Commentary on “Health economics and the value of therapy in Alzheimer's disease.” Cholinesterase inhibitors in Alzheimer's disease—Evidence‐based or evidence‐biased?

    Article • Alzheimer s & Dementia, July 2007, Wiley

    Krista L Lanctot

  86. The contribution of neuropsychiatric symptoms to the cost of dementia care

    Article • International Journal of Geriatric Psychiatry, September 2006, Wiley

    Krista L Lanctot

  87. Behavioral correlates of GABAergic disruption in Alzheimer's disease

    Article • International Psychogeriatrics, July 2006, Cambridge University Press

    Krista L Lanctot

  88. Medial Temporal Hypoperfusion and Aggression in Alzheimer Disease

    Article • Archives of Neurology, November 2004, American Medical Association (AMA)

    Krista L Lanctot

  89. Growth hormone response to clonidine predicts aggression in Alzheimer’s disease

    Article • Psychoneuroendocrinology, October 2004, Elsevier

    Krista L Lanctot

  90. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease

    Article • Expert Opinion on Drug Safety, September 2004, Informa Healthcare

    Krista L Lanctot

  91. Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer’s Disease Patients

    Article • Journal of Psychopharmacology, June 2004, SAGE Publications

    Krista L Lanctot

  92. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia

    Article • Journal of Medical Economics, January 2001, Informa Healthcare

    Krista L Lanctot

  93. Effectiveness of Gabapentin for the Treatment of Behavioral Disorders in Dementia

    Article • Journal of Clinical Psychopharmacology, February 2000, Wolters Kluwer Health

    Krista L Lanctot

  94. Efficacy and Safety of Neuroleptics in Behavioral Disorders Associated With Dementia

    Article • The Journal of Clinical Psychiatry, October 1998, Physicians Postgraduate Press, Inc

    Krista L Lanctot

  95. Behavioural Disorders in Demented Elderly Patients

    Article • CNS Drugs, October 1996, Springer Science + Business Media

    Krista L Lanctot

  96. Comparative Study on Benzodiazepine Use in Canada and Chile

    Article • The Journal of Clinical Pharmacology, February 1993, Wiley

    Krista L Lanctot